Marco Investment Management LLC Acquires 930 Shares of Exact Sciences Co. (NASDAQ:EXAS)

Marco Investment Management LLC grew its holdings in shares of Exact Sciences Co. (NASDAQ:EXAS) by 1.1% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 83,285 shares of the medical research company’s stock after buying an additional 930 shares during the period. Marco Investment Management LLC’s holdings in Exact Sciences were worth $6,161,000 as of its most recent SEC filing.

A number of other hedge funds have also recently modified their holdings of the business. Strategic Blueprint LLC boosted its holdings in shares of Exact Sciences by 3.1% during the 3rd quarter. Strategic Blueprint LLC now owns 5,449 shares of the medical research company’s stock valued at $372,000 after buying an additional 163 shares in the last quarter. Valley National Advisers Inc. raised its position in shares of Exact Sciences by 29.5% in the 3rd quarter. Valley National Advisers Inc. now owns 773 shares of the medical research company’s stock worth $53,000 after purchasing an additional 176 shares during the last quarter. Cullen Frost Bankers Inc. raised its position in shares of Exact Sciences by 40.0% in the 3rd quarter. Cullen Frost Bankers Inc. now owns 700 shares of the medical research company’s stock worth $48,000 after purchasing an additional 200 shares during the last quarter. Nisa Investment Advisors LLC raised its position in shares of Exact Sciences by 0.6% in the 4th quarter. Nisa Investment Advisors LLC now owns 37,200 shares of the medical research company’s stock worth $2,752,000 after purchasing an additional 205 shares during the last quarter. Finally, Xponance Inc. raised its position in shares of Exact Sciences by 1.8% in the 3rd quarter. Xponance Inc. now owns 13,073 shares of the medical research company’s stock worth $892,000 after purchasing an additional 235 shares during the last quarter. Institutional investors own 88.82% of the company’s stock.

Insider Activity at Exact Sciences

In related news, CEO Kevin T. Conroy sold 14,791 shares of the business’s stock in a transaction that occurred on Thursday, February 15th. The stock was sold at an average price of $61.43, for a total transaction of $908,611.13. Following the completion of the transaction, the chief executive officer now directly owns 1,224,357 shares in the company, valued at approximately $75,212,250.51. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. In other Exact Sciences news, EVP Sarah Condella sold 965 shares of the company’s stock in a transaction that occurred on Thursday, February 15th. The stock was sold at an average price of $61.43, for a total value of $59,279.95. Following the completion of the transaction, the executive vice president now directly owns 70,489 shares in the company, valued at approximately $4,330,139.27. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Kevin T. Conroy sold 14,791 shares of the company’s stock in a transaction that occurred on Thursday, February 15th. The stock was sold at an average price of $61.43, for a total value of $908,611.13. Following the completion of the transaction, the chief executive officer now owns 1,224,357 shares of the company’s stock, valued at $75,212,250.51. The disclosure for this sale can be found here. In the last ninety days, insiders sold 69,113 shares of company stock worth $4,165,273. 1.30% of the stock is owned by company insiders.

Exact Sciences Stock Performance

Shares of Exact Sciences stock traded up $0.06 during trading hours on Friday, reaching $58.85. 2,019,062 shares of the stock traded hands, compared to its average volume of 2,963,292. The company has a 50 day moving average price of $63.44 and a 200 day moving average price of $64.93. The firm has a market capitalization of $10.68 billion, a price-to-earnings ratio of -51.62 and a beta of 1.25. Exact Sciences Co. has a one year low of $56.05 and a one year high of $100.77. The company has a quick ratio of 2.07, a current ratio of 2.32 and a debt-to-equity ratio of 0.74.

Exact Sciences (NASDAQ:EXAS) last released its quarterly earnings results on Wednesday, February 21st. The medical research company reported ($0.27) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.53) by $0.26. The business had revenue of $646.89 million during the quarter, compared to the consensus estimate of $638.83 million. Exact Sciences had a negative return on equity of 6.60% and a negative net margin of 8.17%. The business’s quarterly revenue was up 17.0% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.72) EPS. On average, equities research analysts expect that Exact Sciences Co. will post -0.86 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on EXAS shares. William Blair reaffirmed an “outperform” rating on shares of Exact Sciences in a research report on Thursday, February 22nd. Canaccord Genuity Group lowered their price target on Exact Sciences from $100.00 to $90.00 and set a “buy” rating for the company in a research report on Thursday, February 22nd. TheStreet lowered Exact Sciences from a “c-” rating to a “d+” rating in a research report on Monday, February 26th. Benchmark raised Exact Sciences from a “hold” rating to a “buy” rating and set a $91.00 target price for the company in a research report on Tuesday, January 2nd. Finally, Citigroup reissued a “buy” rating and issued a $100.00 target price on shares of Exact Sciences in a research report on Wednesday, April 3rd. Three equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $97.44.

Exact Sciences Company Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.